

### **INTRODUCTION**

Clinical research is vitally important as it is the foundation to provide evidence to improve patient care. This online symposium is to focus on the effect of COVID-19 pandemic on the global clinical research (trials) setting.

In addition to the COVID-19 research, how clinical research in various fields other than the COVID-19 has been managed will be introduced in this symposium.

## TWO DAYS ONLINE SYMPOSIUM

Day 1 Thursday, March 11, 2021 15:25 – 18:40 JST (6:25 - 9:40 UTC)

Day 2 Friday, March 12, 2021 15:25 – 17:55 JST (6:25-8:55 UTC)

### List of abstract

### WHO SHOULD ATTEND??

Health professionals from our partners within countries, who are involved or willing to be involved in clinical research (trials) from the design to the implementation.

# GET CERTIFICATE and DOWNLOADABLE MATERIALS!!



Zoom link and ID will be sent via email to each registrant

### REGISTRATION LINK





	Day 1 March 11, 2021 15:25 - 18:40 (6:25 - 9:40 UTC)	Day 2 March 12, 2021 15:25 – 17:55 (6:25-8:55 UTC)
	15:25-15:30 OPENING	15:25-15:30 OPENING
Q	15:30-15:35 Opening Remarks Dr. Norihiro Kokudo, President of National Center for Global Health and Medicine	15:30 -15.50 Introductory note: Regulatory perspectives for the R&D on COVID19 Mika Togashi Principal Coordinator, Office of International Programs, PMDA, Japan
Ş	15.35-15.45 Developing and maintaining an international clinical trial network activity Dr. Tatsuo liyama Director of Department of International Trials, NCGM	15:50 - 16:20 Keynote Speech: Confronting COVID-19 and the next emergin diseases. Dr Wataru Sugiura Director, Center for Clinical Sciences, NCGM
In this ses therapeutic	15:45-18:35 Session 1: The New normal for Clinical trials iir: Hamana Mieko (NCGM-DIT); Co-chair: Muchanga Sifa (NCGM-DIT) sion, the audience will learn how clinical researches have been managed in various areas in COVID-19 affected environment. The session will provide the audience with portunity to think of how clinical researches are managed under the constraint.	16:20-17:47 Session 2: COVID-19 clinical studies "Learning from front-line health workers" Chair: Muchanga Sifa (NCGM-DIT); Co-chair: Marlinang Siburian (NCGM-DIT) This session provides an opportunity to directly learn how actual clinical trials were developed and managed from the specialists who were engaged in Covid-19 patient care at front line and to think of the implication towards the future.
	15:45 –16:05 Impact of COVID-19 on Infectious diseases research (trials) Dr. Norio Ohmagari, M.D., M.Sc., Ph.D. Director, Disease Control and Prevention Center, NCGM	16:20 – 16:40 COVID-19 at Kinshasa University Clinics (CUK): Epidemioclinical profile and mortality predictors Dr. Mandina Ndona Director, Institute for Research in Health Science (IRSS), Senior Coordinator of the COVID-19 Response at the Kinshasa University Clinics, DRCongo
9	16:05-16:25 Impact of COVID-19 on cancer clinical trials Dr. Kenichi Nakamura Director, National Cancer Center	16:40 – 17:00 Management of COVID19 patients: The Philippines experience Dr. Jubert Benedicto Chief of Critical Care Units Management Team (CCU-MAT)
1	16:25-16:45 Clinical trials in resource limited settings: An example of Leishmaniaisis East Africa Platform (LEAP) Dr. Monique Wasunna Director, DNDi Africa	17:00 - 17:20 Management of COVID19 patients: Indonesia clinical study   Dr Vivi Lisdawati   Director of Research on Infectious and Communicable Diseases, Sulianti Saroso   -Infectious Disease Hospital, Indonesia
	16:45 – 17:15 Keynote Speech: Impact of the COVID-19 pandemic on the management of the Intensive Care and the battle of implementing treatment for a new and unknown disease. Mehran Monchi Head of Department of Intensive Care Medicine, Melun General Hospital, France	17:20 -17:40 The experience of clinical research at the NCGM site   Dr Sho Saito   Clinical Investigator, Disease Control and Prevention Center, NCGM
<b>G</b>	17:15- 17:35 Clinical Research between Thailand and Japan in orthopedics Dr. Tsuyoshi Murase Division of Medicine, Graduate School of Medicine, Associate Professor, Osaka University	17:40 –17:47 Young researcher observations on the management of Covid-1 in Bangladesh Tania Tabassum Global Clinical Research Support Group, Department of Medical Innovation, Osaka University Hospital
	17:35- 17:55 Collaborative study of Prospective, MUlticenteR, Observational StUdy of the PatlenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT HFPEF) between Japan and Cambodia	17:47-17:52 WRAP UP
		17:52-17:55 CLOSING NOTE (Masato Ichikawa, NCGM-DIT)
	Dr. Daisaku Nakatani Head of Global Clinical Research Support Group, Department of Medical Innovation, Osaka University Hospital	
Ø	17:55-18:15 Malaria elimination during COVID-19 era Professor Srivicha Krudsood Deputy Director, WHO CC for Clinical Management of Malaria, Faculty of Tropical Medicine. Mahidol University	
S	18:15- 18:35 Clinical trials for devices and IVD other than COVID-19 device (malaria) Dr. Shigeyuki Kano Director of the Department of Tropical Medicine and Malaria, NCGM	
	18:35-18:40 WRAP UP	

#### Contact info

ditcapacitybuilding@hosp.ncgm.go.jp

Department of International Trials

Center for Clinical Sciences National Center for Global Health and Medicine 1-21-1,Toyama Shinjuku-ku, Tokyo 162-8655 Japan Tel : 81-3-6228-0445 Fax : 81-3-6228-0486

### Visit our webpage



DIT webpage



NCGM webpage